23 Jul, 2026
The global COPD and asthma devices market size reached USD 49.81 billion in 2025 and is anticipated to grow from USD 52.35 billion in 2026 to USD 77.93 billion by 2034, expanding at a CAGR of 5.1% over the forecast period from 2026 to 2034.
COPD and asthma devices, also referred to as pulmonary drug delivery devices are used as a permanent treatment or rescue therapy for respiratory diseases and other related conditions. It is the most advanced method of drug administration because the drug is delivered directly to the lungs for a systemic effect. COPD and asthma hold significant market shares for respiratory diseases worldwide. Various drug delivery protocols, such as oral and parenteral delivery, are developed for treating COPD and asthma. In contrast to other conventional treatment options, the pulmonary drug delivery system is the most effective.
Portable aerosol inhalers permit selective treatment for COPD and asthma due to their ability to achieve high drug concentrations in the airway while minimizing systemic side effects through manual control of systemic drug levels. 2-agonists (portable bronchodilators) have a quicker onset of action than oral medications. Some drugs are only effective when administered via aerosol. A portable aerosol drug delivery system is a convenient and painless option for drug administration. However, training is required on the specific inhalation techniques for correctly using various portable inhaler devices, as suboptimal technology may result in decreased drug delivery. These factors are expected to drive the global adoption of COPD and asthma devices.
Smart inhalers manage breathing flow and data. The trend toward designing Bluetooth-enabled smart devices that are more intuitive driving patient engagement and adherence while increasing treatment effectiveness. Furthermore, next-generation inhalers in development incorporate digital interfaces to manage and adapt patients' breathing patterns. These devices understand the way the patient is breathing and coach him/her to breathe at the appropriate rate. Hence, the development of these devices aids in the specific and accurate delivery of medicaments in asthmatic conditions. Owing to these benefits, the adoption of these devices is likely to fuel the growth of the COPD and asthma devices market.
On the basis of geography, Global COPD and Asthma Devices Market have been divided into North America, Europe, Asia Pacific, and LAMEA.
In 2021, North America was anticipated to be the highest-earning region. COPD ranks third among North America's leading causes of death, behind cancer and cardiovascular disease. COPD is primarily caused by a combination of environmental and lifestyle factors. Additionally, cigarette smoking, air pollution, respiratory allergies, and genetic factors contribute to COPD development.
Due to increased disease awareness, an increase in the patient pool of pediatric asthma and geriatric population susceptible to COPD, and the introduction of new and innovative therapies, the European market for COPD and asthma devices has expanded rapidly. Further, MDIs contain chlorofluorocarbons (CFCs) as propellants, which deplete the ozone layer. Hence, regulatory approval for MDIs has become a major concern in the industry.
The Asia-Pacific accounted for the fastest-growing region in 2021. The Asia-Pacific COPD and asthma devices market includes countries such as India, China, Japan, and Australia, among others. 90% of deaths were attributable to COPD and asthma, with the majority occurring in the Asia-Pacific region's low- and middle-income countries.
The markets considered in this region include Latin America, the Middle East, and Africa. The growing geriatric population, rise in the prevalence of diseases and increase in industrial exhaust gases and automotive gases, among others, have fueled the incidence rate of COPD and asthma in the LAMEA region.
sales@straitsresearch.com